Abstract

The ability to differentiate embryonic stem cells (ESCs) into specific cell types is critical for improved regenerative medicine strategies, cancer chemotherapeutic approaches, and regimens to combat chronic diseases associated with aging. Subclasses of motor neurons (MNs) are generated at different positions along the rostrocaudal axis of the spinal cord, and the signals that specify MN subtype fates remain poorly defined. We show here that the cytochrome P450 enzyme Cyp26a1, which metabolizes all-trans-retinoic acid (RA) and thereby reduces RA levels, plays a crucial role in specifying MN columnar subtypes. Lack of Cyp26a1 in ESCs during differentiation to spinal MNs increases Aldh1a2 (RALDH2) and Hoxc6, markers of the Hox-dependent, lateral motor column (LMC) subtype identity. In contrast, Lhx3, a marker for median motor column identity, showed lower expression in Cyp26a1(-/-)-derived MNs compared with WT. Without Cyp26a1, an increase in intracellular RA concentration plus sonic hedgehog agonist treatment confer an LMC fate on differentiating MNs. Our data suggest a strategy for increasing LMC-type MNs from ESCs by blocking Cyp26a1 in cell replacement/ESC differentiation therapy to treat neurodegenerative diseases, such as amyotrophic lateral sclerosis.

Highlights

  • How to differentiate embryonic stem cells into specific neuronal types is a key question

  • embryonic stem cells (ESCs) were cultured as embryoid bodies (EBs), and on day 2 of the differentiation protocol, the EBs were treated with 1 ␮M retinoic acid (RA) and 1 ␮M sonic hedgehog agonist (Hh Ag-1.3, indicated as SHH throughout) (7, 21)

  • We determined that the cell numbers of wild type (WT) and Cyp26a1Ϫ/Ϫ ESCs treated with this protocol for 7 days with RA and SHH were very similar

Read more

Summary

Background

How to differentiate embryonic stem cells into specific neuronal types is a key question. Lack of Cyp26a1 in ESCs during differentiation to spinal MNs increases Aldh1a2 (RALDH2) and Hoxc, markers of the Hox-dependent, lateral motor column (LMC) subtype identity. To test the function of the cytochrome p450 enzyme Cyp26a1 (Gene ID: 13082) in specifying MNs, we subjected Cyp26a1Ϫ/Ϫ ESCs (14) to an MN differentiation protocol (15) and assessed the molecular phenotype of the resulting MNs. Our results show a significant role for Cyp26a1 and RA in the specification of MN subtype identities and provide insight into how Cyp26a1 inhibition could be used for cell differentiation therapies to generate a reliable source of specified LMC MNs. We show that treatment of ESCs that lack Cyp26a1 with an Shh ago-. Product size bp 272 143 166 140 145 154 132 206 184 180 189 195 195 186 169 154 160 198 nist and RA leads to the differentiation of MNs specific to the LMC

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call